The company says the system can benefit pharmaceutical and biotech firms seeking rapid feedback on drug candidates or genome editing.
A man with neurofibromas who didn't know he's been clinically diagnosed with NF1, learns he harbors a deeply intronic, likely ...
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has received 510(k) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback